News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Announces Court Adopts All Relevant Teva Claim Construction Interpretations in Copaxone® Patent Infringement Case Against Sandoz, Inc./Momenta Pharmaceuticals, Inc. (MNTA) and Mylan Pharmaceuticals, Inc. (MYL)/Natco Pharma Limited; Court Denies Mylan’s Summary Judgment Motion of Invalidity


8/29/2011 10:16:18 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. District Court for the Southern District of New York has issued a favorable set of claim construction rulings in the Company’s patent infringement lawsuit against Sandoz Inc./Momenta Pharmaceuticals, Inc. and Mylan/Natco regarding Teva’s multiple sclerosis (MS) product, Copaxone®. The Court adopted all relevant Teva claim construction interpretations and rejected all of the claim construction interpretations put forth by Sandoz/Momenta and Mylan/Natco. In addition, the Court denied Mylan’s motion for summary judgment that the patents at issue are invalid for indefiniteness.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES